JP2025510813A5 - - Google Patents
Info
- Publication number
- JP2025510813A5 JP2025510813A5 JP2024556626A JP2024556626A JP2025510813A5 JP 2025510813 A5 JP2025510813 A5 JP 2025510813A5 JP 2024556626 A JP2024556626 A JP 2024556626A JP 2024556626 A JP2024556626 A JP 2024556626A JP 2025510813 A5 JP2025510813 A5 JP 2025510813A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- points
- psoriasis
- pharmaceutical composition
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269943P | 2022-03-25 | 2022-03-25 | |
| US63/269,943 | 2022-03-25 | ||
| US202263371033P | 2022-08-10 | 2022-08-10 | |
| US63/371,033 | 2022-08-10 | ||
| US202363490664P | 2023-03-16 | 2023-03-16 | |
| US63/490,664 | 2023-03-16 | ||
| PCT/US2023/064902 WO2023183901A1 (en) | 2022-03-25 | 2023-03-24 | Tyk2 inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510813A JP2025510813A (ja) | 2025-04-15 |
| JP2025510813A5 true JP2025510813A5 (enExample) | 2026-03-31 |
Family
ID=88102041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556626A Pending JP2025510813A (ja) | 2022-03-25 | 2023-03-24 | Ｔｙｋ２阻害剤及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250213572A1 (enExample) |
| EP (1) | EP4499104A4 (enExample) |
| JP (1) | JP2025510813A (enExample) |
| KR (1) | KR20240165963A (enExample) |
| AU (1) | AU2023237900A1 (enExample) |
| CA (1) | CA3246157A1 (enExample) |
| CL (1) | CL2024002824A1 (enExample) |
| MX (1) | MX2024011693A (enExample) |
| TW (1) | TW202345799A (enExample) |
| WO (1) | WO2023183901A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024263861A2 (en) * | 2023-06-23 | 2024-12-26 | Dana-Farber Cancer Institute, Inc. | Methods of treating chronic lymphocytic leukemia |
| EP4780462A1 (en) * | 2023-09-21 | 2026-07-29 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
| CN122341608A (zh) * | 2023-11-24 | 2026-07-03 | 苏州科睿思制药有限公司 | Zasocitinib的晶型及其制备方法和用途 |
| WO2026032374A1 (zh) * | 2024-08-07 | 2026-02-12 | 正大天晴药业集团股份有限公司 | 含联环的化合物用于治疗银屑病的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL317854A (en) * | 2017-07-28 | 2025-02-01 | Takeda Pharmaceuticals Co | TYK2 inhibitors and their uses |
| JP7619951B2 (ja) * | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| US11357775B2 (en) * | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
-
2023
- 2023-03-24 KR KR1020247032947A patent/KR20240165963A/ko active Pending
- 2023-03-24 WO PCT/US2023/064902 patent/WO2023183901A1/en not_active Ceased
- 2023-03-24 US US18/850,466 patent/US20250213572A1/en active Pending
- 2023-03-24 JP JP2024556626A patent/JP2025510813A/ja active Pending
- 2023-03-24 CA CA3246157A patent/CA3246157A1/en active Pending
- 2023-03-24 EP EP23775910.5A patent/EP4499104A4/en active Pending
- 2023-03-24 AU AU2023237900A patent/AU2023237900A1/en active Pending
- 2023-03-25 TW TW112111352A patent/TW202345799A/zh unknown
-
2024
- 2024-09-23 CL CL2024002824A patent/CL2024002824A1/es unknown
- 2024-09-24 MX MX2024011693A patent/MX2024011693A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240325371A1 (en) | Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma | |
| Brown et al. | Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials | |
| JP6837486B2 (ja) | 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法 | |
| CN105228622B (zh) | 用于治疗多发性硬化的PPARγ激动剂 | |
| EP4275750B1 (en) | Treatment of alzheimer's disease in a particular patient population | |
| DE60008143T2 (de) | Lipoxin-a4 und deren analoge zur behandlung von trockenen augen | |
| WO2011111143A1 (ja) | 関節リウマチ薬 | |
| CN118453559A (zh) | 炎症性疾病或骨病的预防或治疗剂及医药组合物 | |
| US20240408102A1 (en) | Resmetirom for reducing liver volume | |
| JP2023538278A (ja) | 中等度から重度の喘息の治療におけるデクスプラミペキソールの使用 | |
| JP2022533981A5 (enExample) | ||
| EP0562705B1 (en) | Use of L-deprenyl for the manufacture of a medicament for the treatment of Cushing's Disease | |
| JP6535678B2 (ja) | 視神経脊髄炎を治療するためのクラドリビンの使用 | |
| WO2008061456A1 (en) | The folacin-metformin compound and its manufacture | |
| US20060069075A1 (en) | Methods for treating dry eye | |
| JP2024545496A5 (enExample) | ||
| US20210393549A1 (en) | New use of R-enantiomer of adrenergic beta 2 receptor agonists for treatment of inflammatory bowel disease and its extra intestinal manifestations | |
| JP2024543345A5 (enExample) | ||
| WO2013054940A1 (ja) | 脱髄疾患の治療薬及び予防薬 | |
| CN112118844A (zh) | 含吲哚化合物的多发性硬化症治疗剂或预防剂 | |
| JP2023538419A5 (enExample) | ||
| Lyons et al. | Topical flurbiprofen: an effective treatment for episcleritis? | |
| US20220362230A1 (en) | Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling | |
| DE60007548T2 (de) | Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit | |
| AU2010270425B2 (en) | Use of benzydamine in the treatment of p40-dependent diseases |